Healthcare Strategy · Pharmacogenomics · Health Economics · Clinical Workflow Design
PGxBridge is a healthcare systems strategy project designed to accelerate pharmacogenomic adoption in Australian clinical practice. The project responds to a structural gap in precision medicine: pharmacogenomic science is clinically useful, but it remains disconnected from the real prescribing workflow. Instead of framing the solution as a standalone app, PGxBridge proposes a national precision prescribing infrastructure layer that embeds genomic intelligence directly into electronic medication ordering. The proposed model integrates four components: smart prescription triggers, rapid PGx testing pathways, clinician-facing decision support, and a reimbursement strategy through pilot subsidies, insurer co-funding, and eventual MBS integration.
Pharmacogenomics remains outside routine prescribing workflows, creating clinical, operational, and reimbursement friction.
The adoption gap is not caused by weak science, but by poor system integration at the moment prescriptions are written.
Embed PGx intelligence into EHR prescribing through trigger-based testing, rapid workflows, and actionable clinical decision support.
This project helped me understand that healthcare innovation is rarely won by technology alone. The hardest part is not proving that pharmacogenomics works scientifically, but designing a system where clinicians can actually use it at the point of care. The strongest learning was the importance of workflow-native design. A recommendation is only valuable if it appears at the exact moment a clinical decision is being made, in a form that reduces cognitive load rather than adding another task. This shaped the entire PGxBridge logic: clinicians should not need to interpret raw alleles; the system should translate genomic evidence into prescribing decisions. Another key reflection was the role of business strategy in healthcare systems. Reimbursement, stakeholder incentives, implementation sequencing, and operational feasibility are not secondary details — they determine whether a clinical innovation scales. The project pushed me to think like a healthcare strategy consultant: define the adoption bottleneck, identify the highest-ROI starting point, build a credible pilot, and connect the solution to system-level economics. Overall, PGxBridge became less of a product mockup and more of a strategic infrastructure proposal for precision medicine adoption.